Relative FOXM1and Met protein levels (normalized to GAPDH)

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.

Advertisements

Supplementary FIGURE 3 LSC segmentation scheme Tumor FNAs.

NPV-BEZ235PKI-587 GDC-0980PD Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD

Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.

Effects of declining sorafenib levels and dose on acquired reversible resistance and toxicity in hepatocellular carcinoma Elizabeth A. Kuczynski, Christina.

B Fold Enrichment (Lep vs Mock) Positive regulation of cell differentiation Negative regulation of epithelial-mesenchymal- transition Cell junction.

Herceptin + 17-AAG Combination BT-474 Tumors

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

B C Supplementary Figure 1 Control X0 Control X9  -HBx (mAb)  -HBx (rabbit serum) ABCEFD aa ABCEF X0 X9 (  D) A

Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.

Supplementary Figure SU11274 PHA SGX EGF/bFGF HGF SU11274 PHA SGX523 A. B

Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC % of Viable Cells  AGR2(nM)

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%

A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) Stat3:Stat3 % of Cont Supplementary Figures Fig. S1 -

Dox E17K WT Basal mediumGrowth medium p-AKT S473 FLAG PI3K  p-AKT T308 p-mTOR S2448 p-mTOR S2481 mTOR Actin Davies BR et al. Supplementary.

Kudo-Saito, et al Supplementary Figure 1 Leukocytes Lymphocytes Debris Dead cells Human PBMCs.

B16 4T1 CT26 FL 72kD Cleaved 45kD (a) (b) Supplemenatry fig. 1 Full length (FL) and cleaved DR6 expression in B16, 4T1 and CT26 cells.

The reading is 7.38 mm. The reading is 7.72 mm.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Shimura Supplemental Figure 1

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

A B C D ** CpG-free Luc -7,200 -5,900 e2piNOS-luc -4,900 e1piNOS-luc

From: Vascular Endothelial Growth Factor Induces MEF2C and MEF2-Dependent Activity in Endothelial Cells Invest. Ophthalmol. Vis. Sci ;49(8):

Figure 1 C. LDH release D. Cell viability E. Cell proliferation

(fold change of miR-cont)

HMGA2 Maintains Oncogenic RAS-Induced Epithelial-Mesenchymal Transition in Human Pancreatic Cancer Cells Sugiko Watanabe, Yasuaki Ueda, Shin-ichi Akaboshi,

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

Cell Physiol Biochem 2017;44:1867– DOI: /

Volume 144, Issue 3, Pages e4 (March 2013)

Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl

Volume 127, Issue 2, Pages (August 2004)

Volume 23, Issue 3, Pages (April 2018)

Bortezomib 1nM PU.1 GAPDH KMS12PE U266 U937 Supplemental Figure S1.

Supplemental Information

Volume 139, Issue 6, Pages (December 2010)

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

Transcriptional activities of c-MYB and A-MYB fusion proteins.

Volume 22, Issue 2, Pages (August 2012)

Overexpression of PRAS40T246A in the Proliferative Compartment Suppresses mTORC1 Signaling, Keratinocyte Migration, and Skin Tumor Development Okkyung.

Volume 138, Issue 5, Pages e2 (May 2010)

Arsenite-Mediated Promotion of Anchorage-Independent Growth of HaCaT Cells through Placental Growth Factor Ichiro Yajima, Mayuko Y. Kumasaka, Shoko Ohnuma,

Figure S2 Supplementary data a b CCA1 CCA2 CCA4 CCA3 CCA5 EGFR HER2

Supplementary Figure 2. AKT1 AKT1 AKT2 pAKT ERK pERK A1847 A2780 CaOV3

Volume 134, Issue 5, Pages (May 2008)

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression Yingjian Li, Bradley C.

Volume 64, Issue 1, Pages (July 2003)

Supplementary Figure S1

Histamine Enhances the Production of Granulocyte-Macrophage Colony-Stimulating Factor via Protein Kinase Cα and Extracellular Signal-Regulated Kinase.

Bo-Kuan Wu, Charles Brenner Cell Reports

Bernard et al, Supplementary Figure S1

Volume 4, Issue 4, Pages (August 2013)

JNK Regulates Autocrine Expression of TGF-β1

Supplementary Fig. S1 BCL2 5’flanking ctrl siRNA luc

An Intronic Enhancer Driven by NF-κB Contributes to Transcriptional Regulation of Peptidylarginine Deiminase Type I Gene in Human Keratinocytes Shibo.

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

The p73 Gene Is an Anti-Tumoral Target of the RARβ/γ-Selective Retinoid Tazarotene Marina Papoutsaki, Mauro Lanza, Barbara Marinari, Steven Nisticò, Francesca.

Volume 126, Issue 4, Pages (April 2004)

Overexpression of HGF decreases MET protein levels.

Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.

A 4h of treatment 72h of treatment 1mM PI3Kbi

The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2 Cheng-Cao Sun, Ling Zhang, Guang.

Molecular Therapy - Nucleic Acids

Mechanism of Akt1 in promoting reprogramming.

Supplemental Figure 1 Cell proliferation (% of mock)

pERK ERK pSTAT1 STAT1 pSTAT3 STAT3 pAKT AKT

Figure 2. p62−/−MEF cells enhance the activation of NF-κB induced by TLR4. (A) Wild-type (WT) p62+/+MEF and p62−/−MEF cells were transfected with pBIIx-luc.

Western blotting confirming the presence of fusion proteins in tumor lysates and showing increased signaling pathway activation in respective tumors. Western.

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

Volume 21, Issue 4, Pages (February 2006)

Presentation transcript:

Relative FOXM1and Met protein levels (normalized to GAPDH) Supplementary Figure S1 (New) Relative FOXM1and Met protein levels (normalized to GAPDH) B M C pF FOXM1 Met A Si siCtr (nmol) siFOXM1 (nmol) 100 50 GAPDH BxPC-3 pCtr (mg) pFOXM1 (mg) 2 1 Colo357 Fold 1.0 1.1 5.3 8.9 2.6 4.1 1.2 0.4 0.1 0.3 “M”, Mock; “C”, SiControl; “Si”, SiFOXM1 “M”, Mock; “C”, Control vector; “pF”, pFOXM1

A B C Supplementary Figure S2 (New) Relative Met promoter DNA (%, normalized to Input) (Fold, normalized to Input) #2 and #1 : 5’-TTATTTAATCAGCCTGCTTCCGGCTATG-3’ (-816 to -788) #3: 5’-AAAGCTCTTTTTTAAAAATCATCATAAG-3’ (-905 to -877) pLuc-Met-580 +1 Luc +236 -344 pLuc-Met-1069 -833 #2 #1 pLuc-Met-1259 -1023 #2 #1 #3 A Relatvie promoter activity (%) activity (fold) C FG PANC-1 Putative FOXM1-binding sites on Met promoter

Relative levels (normalized to GAPDH) Supplementary Figure S3 (New) Relative levels (normalized to GAPDH) FG AsPC-1

A B Supplementary Figure S4 (New) AsPC-1 FG FOXM1 p-Met pAKT GAPDH pERK1/2 pSTAT3 AsPC-1 FG Met siControl HGF+siControl HGF+siMet#1 HGF+siMet#2 Control HGF HGF+PHA ERK1/2 AKT STAT3 A B Fold 1.0 4.0 1.2 0.4 4.3 0.3 2.8 0.2 8.5 2.2 3.1 5.3 2.1 1.1 7.5 1.8 0.. 8.9 5.1 1.6 6.5 2.7 4.1 0.8 6.9 2.5 1.5 3.8 2.6 3.4 2.3 2.9

FG Relative promoter activity (fold) Supplementary Figure S5 (New) FG Relative promoter activity (fold) 0.2 0.01 0.6 Cyclin B1-Luc (mg) pRL (mg) pCtr (mg) pFOXM1 (mg) HGF (ng/ml) - 20 PHA-665752 (mM) 0.5 P < 0.001 P = 0.001 PANC-1

Relative protein levels (normalized to GAPDH) Supplementary Figure S6 (New) Relative protein levels (normalized to GAPDH) FG PANC-1

FG PANC-1 Supplementary Figure S7 Relatvie promoter activity (fold) FOXM1-Luc(mg) 0.2 0.2 0.2 0.2 0.2 pRL(mg) 0.01 0.01 0.01 0.01 0.01 pFOXM1(mg) 0.6 0.6 0.6 0.6 0.6 HGF (ng/ml) - 20 20 20 20 FR180204 (mM) - - 10 - - GSK690693(mM) - - - 10 - S3I-201 (mM) - - - - 100 PANC-1 P = 0.004 P = 0.002 P < 0.001 P < 0.001 Relavtive promoter activity (fold) FOXM1-Luc(mg) 0.2 0.2 0.2 0.2 0.2 pRL(mg) 0.01 0.01 0.01 0.01 0.01 pFOXM1(mg) 0.6 0.6 0.6 0.6 0.6 HGF (ng/ml) - 20 20 20 20 FR180204 (mM) - - 10 - - GSK690693(mM) - - - 10 - S3I-201 (mM) - - - - 100

Supplementary Figure S8 Control HGF HGF + siFOXM1 PHA665752 P = 0.002 Colony number P = 0.777 P < 0.001 HGF + siFOXM1 HGF + PHA665752

A B FG Supplementary Figure S9 PANC-1 Tumor weight (g) FOXM1 Met Mock Control pFOXM PANC-1 FOXM1 Met FG pFOXM1 siFOXM1 A siFOXM B P < 0.001 Tumor weight (g) P = 0.014

A B C D E F Supplementary Figure S10 (New) Relative protein levels (normalized to GAPDH) Relative protein levels (normalized to GAPDH) C D Relative protein levels (normalized to GAPDH) Relative protein levels (normalized to GAPDH) E F Relative protein levels (normalized to GAPDH) Relative protein levels (normalized to GAPDH)